insulin degludec

This page shows the latest insulin degludec news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Xultophy (insulin degludec and liraglutide) which rocketed more than 150% in the first six months of the year to 720m krone. ... 80bn krone on price reductions, competition from generic long-acting insulins including insulin glargine, and cannibalisation

Latest news

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Novo Nordisk fends off Lilly’ s GLP-1 challenge in Q1. Insulin specialist bounces back with encouraging signs from Ozempic launch. ... This was despite growth for new long-acting insulin Tresiba (insulin degludec), which grew 33% to DKK 1.75bn in local
CHMP backs first-line use for AZ’s Tagrisso in lung cancer

insulin degludec/liraglutide).
Sanofi wins EU approval for new diabetes combination Suliqua

The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is ... same day as rival therapy Xultophy, Novo
Sanofi launches insulin combo Soliqua in US

Sanofi launches insulin combo Soliqua in US. Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy. ... Soliqua (insulin glargine/lixisenatide) reaches the market ahead of Novo Nordisk's rival combination
FDA clears rival diabetes combos from Sanofi and Novo Nordisk

day. Both products include a long-acting basal insulin coupled with a GLP-1 agonist and are intended for the treatment of patients with type 2 diabetes who are not managing ... In the case of Xultophy, the combination is based on Novo's basal insulin

More from news
Approximately 13 fully matching, plus 59 partially matching documents found.

Latest Intelligence

Interview: Peter Meeus, Novo Nordisk

Vice president sales and marketing, Novo Nordisk. International marketing manager insulin analogues, Novo Nordisk. ... Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical Writer - Creative and Scientific Projects: DOE

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior Account Manager – Healthcare Advertising: Salary TBC

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Writer, Healthcare Advertising, London: Excellent package

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Director or Senior Account Director: Salary TBC

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Healthcare PR Senior Account Manager: Salary TBC

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Healthcare PR Director: £100, 000 – £120, 000 benefits

Systematic Review Lead- London: Negotiable

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Director, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer: Salary is DOE

Senior Training Manager - Surrey: Competitive Salary &Bonus

Associate Scientific Director: Salary TBC

Graduate Scientific Editor: DOE

Subscribe to our email news alerts

PMHub

Add my company

Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...